Mette T. Thomsen

Kongens Lyngby, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Editorial: Reviews in: regulatory science 2024-2025.

Editorial: Reviews in: regulatory science 2024-2025.

Journal: Frontiers in medicine

Published: September 15, 2025

Editorial: Women in science - regulatory science 2023.

Editorial: Women in science - regulatory science 2023.

Journal: Frontiers in medicine

Published: February 21, 2024

Editorial: Women in science-Regulatory science 2021.

Editorial: Women in science-Regulatory science 2021.

Journal: Frontiers in medicine

Published: February 06, 2023

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.

Journal: Diabetes, obesity & metabolism

Published: June 21, 2021

Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.

Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: February 19, 2021

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.

Journal: Obesity (Silver Spring, Md.)

Published: December 20, 2019

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Journal: The New England journal of medicine

Published: June 12, 2019

Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.

Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.

Journal: Clinical pharmacokinetics

Published: April 05, 2019

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.

Journal: Clinical pharmacokinetics

Published: December 20, 2018

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.

Journal: Diabetes, obesity & metabolism

Published: June 20, 2018

Global Pediatric Drug Development.

Global Pediatric Drug Development.

Journal: Current therapeutic research, clinical and experimental

Published: May 08, 2018

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.

Journal: Clinical pharmacokinetics

Published: April 07, 2018

Showing 1-12 of 24

Last Updated: 09/26/2026